<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297141</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG 95 / TAKO 05</org_study_id>
    <secondary_id>Studie R02 (95)</secondary_id>
    <secondary_id>2004-002358-72</secondary_id>
    <nct_id>NCT00297141</nct_id>
  </id_info>
  <brief_title>Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma</brief_title>
  <official_title>Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rate of T-downstaging (Reduction of the T-stadium) at the time of final surgery following the
      preoperative combined radiochemotherapy (chemotherapy: Oxaliplatin, Capecitabine) Evaluation
      of the toxicity grade III and IV of the therapy scheme
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 60 patients with locally advanced rectal carcinoma (cT3, Nx, M0) of the lower and
      middle rectum will be recruited.

      The radiotherapy is an essential part of therapy of the advanced rectal carcinoma and the
      additional administration of a chemotherapy will positively influence the effect of the
      therapy (downstaging-rate, rate of distant metastases, survival-rate). Probably a downsizing
      and downstaging (as per literature and by own experience) can be reached with an preoperative
      combined radiochemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of T-downstaging (Reduction of the T-stadium)</measure>
    <time_frame>at the time of final surgery</time_frame>
    <description>surgery following the preoperative combined radiochemotherapy (chemotherapy: Oxaliplatin, Capecitabine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the toxicity grade III and IV of the therapy scheme</measure>
    <time_frame>week 1 to max. week 10</time_frame>
    <description>from Visit 1 till surgery: weekly visits (visit 1 to visit 5) followed by final examination (performed 1 to 2 weeks after visit 5) before surgery followed by hospital admission (performed 1 to 2 weeks after final examination) followed by surgery ((performed 1 to 2 weeks after hospital admission)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>single arm (radiochemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study (capecitabine, oxaliplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>chemotherapy oral use</description>
    <arm_group_label>single arm (radiochemotherapy)</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>RO 09-1978</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>chemotherapy intravenous use</description>
    <arm_group_label>single arm (radiochemotherapy)</arm_group_label>
    <other_name>treatment defined only by active substance</other_name>
    <other_name>(no trade name defined; investigators choice)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 - 80

          -  Biooptical confirmed adenocarcinoma of the lower und middle rectum (lower edge of the
             tumor located max. 14 cm of the anal verge)

          -  According to MRI tumor extensions into the perirectal fat tissue (cT3)

          -  No former chemotherapy, radiotherapy and/or tumor resection of a rectum carcinoma

          -  WHO performance status 0 - 2

          -  Adequate bone marrow reserve (leucocytes - not more than 3.000/ml; thrombocytes - not
             more than 100.000/ml)

          -  Adequate hepatic function (bilirubin - not more than 1.5 x ULN; GOT and GPT - not more
             than 3.5 x ULN)

          -  Adequate renal function (creatinin - not more than 1.5 mg/dl)

          -  Women of childbearing potential: exclusion of pregnancy (negative urin or serum
             pregnancy test)

          -  Willingness of women of childbearing potential and accordingly of potent men to use
             approved contraceptives (for example birth-control pill, loop, condom) during and at
             least 3 month after closure of the study

          -  Life expectancy of at least 3 month

          -  Signed written Informed Consent before recruitment

          -  Exclusion of distant metastases at the time of recruitment

        Exclusion Criteria:

          -  Former radio- and/or chemotherapy

          -  Tumor of the upper rectum

          -  Any other kind of malign tumor in the last five years (except adequate treated basal
             cell carcinoma of the skin, or in situ cervical carcinoma)

          -  Peripheral Neuropathy (NCI CTC - not higher than Grade 1)

          -  General contraindication or hypersensitivity against Oxaliplatin and/or Capecitabine

          -  Any other untreated not malign diseases: Cardiac insufficiency, angina pectoris,
             hypertension or arrhythmia, hepatic diseases, significant neurological or psychiatric
             disorders

          -  Florid, serious infection at the time of recruitment

          -  Legally limited capacity or evidence of a neurological or psychiatric disease, the
             investigator is the opinion it will constrict the patients compliance

          -  Evidence of lacking willingness for cooperation of the patient

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietmar Oefner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander de Vries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Thaler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital BHB St. Veit/Glan, Surgery</name>
      <address>
        <city>St. Veit a. d. Glan</city>
        <state>Carinthia</state>
        <zip>9330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz, Oncology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Leoben, Surgery</name>
      <address>
        <city>Leoben</city>
        <state>Styria</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck, Surgery</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medical University Salzburg - Oncology</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Radiotherapy</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <last_update_submitted>December 30, 2013</last_update_submitted>
  <last_update_submitted_qc>December 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preoperative</keyword>
  <keyword>Radiochemotherapy</keyword>
  <keyword>Newly Diagnosed</keyword>
  <keyword>Primary Operable</keyword>
  <keyword>Locally Advanced</keyword>
  <keyword>Rectal Carcinoma</keyword>
  <keyword>T3</keyword>
  <keyword>Lower Rectum</keyword>
  <keyword>Middle Rectum</keyword>
  <keyword>ABCSG</keyword>
  <keyword>TAKO</keyword>
  <keyword>95</keyword>
  <keyword>05</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

